



10-29-02

Docket No: GI 5358 CIP
Patent

1614
#7/10
01-15-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
OCT 31 2002
TECH CENTER 1600/2900

In re of Application of: Jacobs, et al
Serial No.: 10/084,298 Group Art No.: 1614
Filed: February 25, 2002 Examiner:
For: COMPOSITION AND METHOD FOR TREATING
INFLAMMATORY DISORDERS
Confirmation No.: 7985
Customer Number: 25291

Assistant Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

1. Preliminary Statements

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

CERTIFICATE OF MAILING 37 CFR §1.10

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EL 953853535 US addressed to the Assistant Commissioner for Patents, Washington, DC 20231.

10/28/02
Date

Kerry A. McCarthy
Kerry A. McCarthy

2. Identification of Time of Filing

This Information Disclosure Statement

- a. ☐ is filed within three months of the filing date of the application.
- b. ☒ is filed before the mailing date of a first Office Action on the merits.
- c. ☐ is filed before the mailing date of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.
- d. ☐ is filed after the period specified in 2(a), 2(b) or 2(c) above, but before the mailing date of a final action under 37 CFR 1.311. This statement includes a certification under 37 CFR 1.97(e) or the fee set forth in 37 CFR 1.17(p).
- e. ☐ is filed after the mailing date of a final action or Notice of Allowance but before payment of the issue fee. This statement includes (i) a certification under 37 CFR 1.97(e), and (ii) the fee set forth in 37 CFR 1.17(p).

3. ☐ Certification under 37 CFR 1.97(e) and 1.704(d)
The undersigned attorney certifies

- a. ☐ that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement, or
- b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the statement.
- c. ☐ The undersigned attorney certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign application patent office in a counterpart foreign application and was not received by any individual designated in 37 CFR 1.56(c) more than thirty (30) days prior to the filing of the statement.

☒ Newly Cited Information
A legible copy of the patents, publications or other information cited on the attached form PTO 1449 is enclosed.

☐ Previously Cited Information
No copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed because it has been previously cited by or submitted to the Office in a prior application which is relied upon for an earlier filing date under 35 USC 120.

Prior application is Serial Number , filed on of for .


- ☐ Concise Explanation
Documents cited above which are not in the English Language
- a. ☐ have been explained in the specification.
- b. ☐ have an abstract (or other concise explanation) in English enclosed or if readily available a translation into English of the document is enclosed.

Form PTO-1449 is enclosed in duplicate.

- ☐ Fees
☐ Fee for filing under 37 CFR 1.97(c) or (d) Fee: \$180.00

Method of Payment of Fees:
Charge Deposit Account No. 07-1060 in the amount of \$0.00
A duplicate of this statement is enclosed.

Instructions as to Overpayment/Underpayment:
Credit any overpayment and charge any underpayment to Deposit Account No. 07-1060.




Diana M. Collazo
Reg. No. 46,635

Wyeth
Patent Law Department
Five Giralda Farms
Madison, NJ 07940
Tel. No. (617) 665-8775

Substitute for form 1449/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Use as many sheets as necessary)

Sheet 1 of 2

Application Number 10/084,298
 Filing Date February 25, 2002
 First Named Inventor Jacobs, et al
 Group Art Unit 1614
 Examiner Name
 Attorney Docket Number GI 5358 CIP

RECEIVED
 OCT 31 2002
 TECH CENTER 160012900

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If known)	Kind Code (If Known)			
	1.	5,350,836-A		Kipchick et al	09-1994	
	2.	5,536,637		Jacobs	07-1996	
	3.	6,359,117		Dumoutier et al	07-16-1999	
	4.	6,331,613		Dumoutier et al	10-18-1999	
	5.	6,274,710		Dumoutier et al	10-26-1998	
	6.	US2001/0024652 A1		Ludwig Institute for Cancer Research	09-27-2001	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If Known)				
	7.		WO 94/01548-A2		Sibson, et al	01-1994		<input type="checkbox"/>
	8.		WO 01/46422 A1		Zymogenetics, Inc.	06-28-2001		
	9.		WO 00/77037 A2		Genentech, Inc.	12-21-2000		
	10.		WO 00/73457 A1		Schering-Corporation	12-07-2000		
	11.		WO 00/70049		Incyte Genomics, Inc.	11-23-2000		
	12.		WO 99/61617		Human Genome Sciences, Inc.	12-02-1999		
	13.		WO 00/24758		Ludwig Institute for Cancer Research	05-04-2000		
	14.		WO 02/10393 A2		Ludwig Institute for Cancer Research	02-07-2002		

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	15.	Mahairas G., et al. Database EST. Accession No. AQ104025. 28 Aug 1998.	<input type="checkbox"/>
	16.	Waterston R., et al. Database GenEmbl. Accession No. AC006734. 25 Feb 1999.	
	17.	Wilson R., et al. J. Mol. Biol. 261:155-172, 1996.	
	18.	Bork, et al. Trends in Genetics 12:425-427, 1996.	
	19.	Vukicevic, et al. PNAS USA 93:9021-9026, 1996.	
	20.	Massague J. Cell 49:437-8, 1987.	
	21.	Pilbeam, et al. Bone 14:717-720, 1993.	
	22.	Skolnick, et al. Trends in Biotech. 18:34-39, 2000.	
	23.	Dumoutier, et al. (2000), "Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9," J. of Immunol. 164:1814-1819.	
	24.	Syrbe, et al. (1999) Springer Seminars in Immunopathology, 21:263-85.	
	25.	Dumoutier, L., et al. GenBank Accession number NM_016971 for mus musculus interleukin 10-related T cell-derived inducible factor (Iltif). 08 Jun 2000.	
	26.	Aoki, I., et al. "Comparison of the amino acid and nucleotide sequences between human and two guinea pig major basic proteins," FEBS Lett. 282(1):56-60, 1991.	
	27.	Dumoutier, L., et al., "Human interleukin-10-related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor," PNAS 97(18):10144-9, 2000.	
	28.	Dumoutier, L., et al., "IL-TIF/IL-22: genomic organization and mapping of the human and mouse genes," Genes Immun. 1:488-494, 2000.	
	29.	Ozaki, T., et al. GenBank Accession number D13973 for Dictyostelium discoideum DNA for Dp87 protein, 1993. 01 Feb 2000.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/084,298
Filing Date	February 25, 2002
First Named Inventor	Jacobs, et al
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	GI 5358 CIP

Sheet

2

of

2

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	30.	Aoki, I., et al. GenBank Accession Number P35709 for Eosinophil granule major basic protein 2 precursor (mbp-2). 30 May 2000.	
	31.	Xie, M., et al GenBank Accession Number AF279437 for Homo sapiens interleukin 22 (IL22). 09 Oct 2000.	
	32.	Dumoutier, L., et al. GenBank Accession Number AJ294727 for Mus musculus ILTIFa gene for IL TIE alpha protein (IL-21), exons 1a 5. 21 Dec 2000.	
	33.	Dumoutier, L., et al. GenBank Accession Number NP_065386 for Interleukin 22; interleukin 21; IL-10-related T-cell-derived inducible factor (homo sapiens). 02 Nov 2000.	
	34.	Ozaki, T., et al., "Developmental regulation of transcription of a novel prespore-specific gene (Dp87) in Dictyostelium discoideum," Development. 117(4):1299-308, 1993.	
	35.	Sambrook, J., et al. Molecular Cloning. A Laboratory Manual, 2d ed. Cold Spring Harbor Laboratory Press, 1989, Ch. 17.	
	36.	Xie, M.H., et al., "Interleukin IL-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R," J. Biol. Chem. 275(40):31335-9, 2000.	

RECEIVED
OCT 5 1 2002
TECH CENTER 1600/2900

S:\LACOMMON\PATENTS\AMEND\5358\CIP\PTO 1449.doc

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(use as many sheets as necessary)

Application Number 10/084,298
Filing Date February 25, 2002
First Named Inventor Jacobs, et al
Group Art Unit 1614
Examiner Name
Attorney Docket Number GI 5358 CIP

RECEIVED
OCT 31 2002
TECH CENTER 1600/2900

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If known)	Kind Code (If Known)			
	1.	5,350,836-A		Kipchick et al	09-1994	
	2.	5,536,637		Jacobs	07-1996	
	3.	6,359,117		Dumoutier et al	07-16-1999	
	4.	6,331,613		Dumoutier et al	10-18-1999	
	5.	6,274,710		Dumoutier et al	10-26-1998	
	6.	US2001/0024652 A1		Ludwig Institute for Cancer Research	09-27-2001	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If Known)				
	7.		WO 94/01548-A2		Sibson, et al	01-1994		<input type="checkbox"/>
	8.		WO 01/46422 A1		Zymogenetics, Inc.	06-28-2001		
	9.		WO 00/77037 A2		Genentech, Inc.	12-21-2000		
	10.		WO 00/73457 A1		Schering-Corporation	12-07-2000		
	11.		WO 00/70049		Incyte Genomics, Inc.	11-23-2000		
	12.		WO 99/61617		Human Genome Sciences, Inc.	12-02-1999		
	13.		WO 00/24758		Ludwig Institute for Cancer Research	05-04-2000		
	14.		WO 02/10393 A2		Ludwig Institute for Cancer Research	02-07-2002		

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	15.	Mahairas G., et al. Database EST. Accession No. AQ104025. 28 Aug 1998.	<input type="checkbox"/>
	16.	Waterston R., et al. Database GenEmbl. Accession No. AC006734. 25 Feb 1999.	
	17.	Wilson R., et al. J. Mol. Biol. 261:155-172, 1996.	
	18.	Bork, et al. Trends in Genetics 12:425-427, 1996.	
	19.	Vukicevic, et al. PNAS USA 93:9021-9026, 1996.	
	20.	Massague J. Cell 49:437-8, 1987.	
	21.	Pilbeam, et al. Bone 14:717-720, 1993.	
	22.	Skolnick, et al. Trends in Biotech. 18:34-39, 2000.	
	23.	Dumoutier, et al. (2000), "Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9," J. of Immunol. 164:1814-1819.	
	24.	Syrbe, et al. (1999) Springer Seminars in Immunopathology, 21:263-85.	
	25.	Dumoutier, L., et al. GenBank Accession number NM_016971 for mus musculus interleukin 10-related T cell-derived inducible factor (Iltif). 08 Jun 2000.	
	26.	Aoki, I., et al. "Comparison of the amino acid and nucleotide sequences between human and two guinea pig major basic proteins," FEBS Lett. 282(1):56-60, 1991.	
	27.	Dumoutier, L., et al., "Human interleukin-10-related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor," PNAS 97(18):10144-9, 2000.	
	28.	Dumoutier, L., et al., "IL-TIF/IL-22: genomic organization and mapping of the human and mouse genes," Genes Immun. 1:488-494, 2000.	
	29.	Ozaki, T., et al. GenBank Accession number D13973 for Dictyostelium discoideum DNA for Dp87 protein, 1993. 01 Feb 2000.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Complete if Known	
		Application Number	10/084,298
		Filing Date	February 25, 2002
		First Named Inventor	Jacobs, et al
		Group Art Unit	1614
		Examiner Name	
Sheet 2 of 2	Attorney Docket Number	GI 5358 CIP	

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	30.	Aoki, I., et al. GenBank Accession Number P35709 for Eosinophil granule major basic protein 2 precursor (mbp-2). 30 May 2000.	
	31.	Xie, M., et al GenBank Accession Number AF279437 for Homo sapiens interleukin 22 (IL22). 09 Oct 2000.	
	32.	Dumoutier, L., et al. GenBank Accession Number AJ294727 for Mus musculus ILTIFa gene for IL TIE alpha protein (IL-21), exons 1a 5. 21 Dec 2000.	
	33.	Dumoutier, L., et al. GenBank Accession Number NP_065386 for Interleukin 22; interleukin 21; IL-10-related T-cell-derived inducible factor (homo sapiens). 02 Nov 2000.	
	34.	Ozaki, T., et al., "Developmental regulation of transcription of a novel prespore-specific gene (Dp87) in Dictyostelium discoideum," Development. 117(4):1299-308, 1993.	
	35.	Sambrook, J., et al. Molecular Cloning. A Laboratory Manual, 2d ed. Cold Spring Harbor Laboratory Press, 1989, Ch. 17.	
	36.	Xie, M.H., et al., "Interleukin IL-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R," J. Biol. Chem. 275(40):31335-9, 2000.	

S:\COMMON\PATENTS\AMEND\5358\CIP\PTO 1449.doc

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.